News & Updates

Show Multimedia Only

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. Patients are increasingly more aware of new and different treatment options and are seeking therapies that align with their personal values. As survival outcomes continue to improve, shared decision-making (SDM) plays a vital role in individualising care by integrating clinical evidence with what matters most to each individual. This article explores how SDM can support patient-centred care, drawing on insights from Professor James Yang and patient advocate Mark Brooke.

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

13 Aug 2025

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025 by

Patients with grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas receiving vorasidenib experience fewer seizure activities than those on placebo, as shown by the results of the INDIGO study.

Vorasidenib prevents seizures in mIDH1/2 gliomas

12 Aug 2025

VIDEO: Professor Fred Saad on ARANOTE findings, implications of PSA response and choosing the most appropriate treatment option for mHSPC patients

12 Aug 2025 by

Prof Fred Saad, Director of GU Oncology at the University of Montreal, Canada, and principal investigator of the ARANOTE trial, discusses ARANOTE findings, implications of PSA response and choosing the most appropriate treatment option for mHSPC patients.

VIDEO: Professor Fred Saad on ARANOTE findings, implications of PSA response and choosing the most appropriate treatment option for mHSPC patients

12 Aug 2025

Adiposity levels may predict CRC risk

11 Aug 2025

High adiposity levels are associated with the risk of colorectal cancer (CRC), suggest the results of a systematic review. However, standardization is necessary to improve understanding of the link between CRC and adiposity to enable comparisons across papers.

Adiposity levels may predict CRC risk

11 Aug 2025

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

07 Aug 2025 by

Tarlatamab was associated with significant improvements in overall survival (OS), progression-free survival (PFS) and patient-reported outcomes (PROs) vs standard-of-care (SoC) chemotherapy in patients with small-cell lung cancer (SCLC) undergoing second-line (2L) therapy, according to the primary analysis of the phase III DeLLphi-304 study presented at ASCO 2025.

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

07 Aug 2025

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

06 Aug 2025 by

Proactive use of scheduled lorazepam or lorazepam plus haloperidol is superior to haloperidol alone in managing refractory agitated delirium in patients with advanced cancer in the palliative care setting, according to results of a multicentre randomized clinical trial (RCT) conducted in Taiwan and the US.

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

06 Aug 2025

No excess liver cancer risk seen with oral contraceptive use

03 Aug 2025 by

Two large prospective cohorts show no evidence of an association between the use of oral contraceptives and the risk of liver cancer.

No excess liver cancer risk seen with oral contraceptive use

03 Aug 2025

Primary sclerosing cholangitis an independent risk factor for colorectal cancer

01 Aug 2025

Primary sclerosing cholangitis (PSC) poses an increased risk of colorectal cancer (CRC), even in the absence of concomitant inflammatory bowel disease (IBD), according to a retrospective study.

Primary sclerosing cholangitis an independent risk factor for colorectal cancer

01 Aug 2025

Polypharmacy, inappropriate medications common in older cancer patients

31 Jul 2025

Older patients with cancer are unusually susceptible to polypharmacy, as well as potentially inappropriate medications and potential drug-drug interactions, reveals a study.

Polypharmacy, inappropriate medications common in older cancer patients

31 Jul 2025

Belantamab mafodotin, bortezomib, dexamethasone triplet scores big in RRMM

31 Jul 2025

Triplet therapy with belantamab mafodotin, bortezomib, and dexamethasone (BVd) significantly improves outcomes in relapsed or refractory multiple myeloma (RRMM), outperforming the daratumumab, bortezomib, and dexamethasone (DVd) combination therapy, according to the second interim analysis of the phase III DREAMM-7 trial.

Belantamab mafodotin, bortezomib, dexamethasone triplet scores big in RRMM

31 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Beyond Survival: Empowering a Future for Patients with EGFR-Mutated NSCLC

Vorasidenib prevents seizures in mIDH1/2 gliomas

Vorasidenib prevents seizures in mIDH1/2 gliomas

VIDEO: Professor Fred Saad on ARANOTE findings, implications of PSA response and choosing the most appropriate treatment option for mHSPC patients

VIDEO: Professor Fred Saad on ARANOTE findings, implications of PSA response and choosing the most appropriate treatment option for mHSPC patients

Adiposity levels may predict CRC risk

Adiposity levels may predict CRC risk

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

DeLLphi-304: Tarlatamab bests SoC chemo as 2L treatment for SCLC

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

Scheduled lorazepam-based regimens superior to haloperidol alone for agitated delirium at end of life

No excess liver cancer risk seen with oral contraceptive use

No excess liver cancer risk seen with oral contraceptive use

Primary sclerosing cholangitis an independent risk factor for colorectal cancer

Primary sclerosing cholangitis an independent risk factor for colorectal cancer

Polypharmacy, inappropriate medications common in older cancer patients

Polypharmacy, inappropriate medications common in older cancer patients

Belantamab mafodotin, bortezomib, dexamethasone triplet scores big in RRMM

Belantamab mafodotin, bortezomib, dexamethasone triplet scores big in RRMM